TY  - RPRT
TI  - Trastuzumab deruxtecan plus pertuzumab in first-line HER2-positive advanced/metastatic breast cancer.
AU  - Sara M Tolaney
AU  - Sibylle Loibl
PY  - 2026
DO  - 10.21037/tcr-2026-1671
UR  - https://pubmed.ncbi.nlm.nih.gov/42724828/
ID  - 42724828
ER  -